Ever since the first immune checkpoint inhibitor was approved for market nearly twelve years ago, the industry has witnessed a steady rise in the search for new immunotherapies. This has aligned with the broader curation of a number of new dose-escalation and efficacy designs for clinical development in oncology.
Hastening the search for novel treatment options therefore benefits from exploration of how these complex early and late-phase designs interact with each other, and what special design considerations can be implemented in early phases of clinical research for strategic late-phase clinical development. A nuanced understanding of these considerations enables sponsors to ask more complex questions like:
Which dose-escalation designs are best suited for trials where the new treatment aspires to join a basket trial in later phases?
Is data acquired using a complex early phase design like BLRM, TITE-BOIN, or dual-agent escalation recommended for use if a seamless design will thereafter be used to confirm efficacy?
What are the adaptive strategies that best serve specific trials?
A recent webinar by Cytel’s Michael Fossler and James Matcham reviews the various trial design considerations confronting modern immunotherapy sponsors. After introducing the relative benefits of a number of algorithm-based and model-based escalation designs, Fossler and Matcham dive into strategic uses of target population, clinical pharmacology considerations, and exposure-response modeling for efficient clinical development.
Taken together, these questions can help sponsors have more in-depth conversations with their statistical design consultants about specific adaptive design and modeling strategies for their immunotherapies.
Watch the full webinar, “Design Considerations for Early Phase Clinical Trials of Immuno-oncology Drugs,” here:
Bayesian topics are frequently featured in Cytel’s Perspectives on Enquiry and Evidence. Our new eBook features a set of articles exploring various topics related to Bayesian statistical methods.
Read more from Perspectives on Enquiry and Evidence:
Sorry no results please clear the filters and try again